Patterns of patient discontinuation from buprenorphine/naloxone treatment for opioid use disorder: A study of a commercially insured population in Massachusetts

Research has shown buprenorphine/naloxone to be an effective medication for treating individuals with opioid use disorder. At the same time, treatment discontinuation rates are reportedly high though much of the extant evidence comes from studies of the Medicaid population. To examine the pattern and determinants of buprenorphine/naloxone treatment discontinuation in a population of commercially insured individuals. We performed a retrospective observational analysis of Massachusetts All Payer Claims Data (MA APCD) covering years 2013 through 2017. We defined treatment discontinuation as a gap of 60 consecutive days without a prescription for buprenorphine/naloxone within a time frame of 24 months from the initiation of treatment. A mixed-effect Cox proportional hazard model examined the associated risk of discontinuing treatment with baseline predictors. A total of 5134 individuals who were commercially insured during the study period. Buprenorphine/naloxone treatment discontinuation. Overall 75% of individuals had discontinued treatment within two years of initiating treatment, and median time to discontinuation was 300 days. Patients aged between 18 and 24 years (HR = 1.436, 95%, CI = 1.240–1.663) and receiving treatment from prescribers with high panel-size (HR = 1.278, 95% CI = 1.112–1.468) had higher risk of discontinuing treatment. On the contrary, patients receiving treatment from multiple prescribers had lower associated risk of treatment discontinuation. A substantial percentage of patients discontinue treatment well before they can typically meet criteria for sustained remission. Further investigations should assess the clinical outcomes following premature discontinuation and identify strategies for retaining patients in treatment. •Little evidence exists on the buprenorphine/naloxone treatment discontinuation for commercially insured patients.•Patient and provider level factors of buprenorphine/naloxone treatment discontinuation are examined.•Substantial percentage of commercially insured patients discontinue treatment within one year of initiation.•High volume prescribers' patients have higher associated risk for treatment discontinuation.